Sat, Aug 2, 2014, 6:19 AM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Aeterna Zentaris Inc. Message Board

mrbutters334 30 posts  |  Last Activity: Jul 30, 2014 11:33 AM Member since: Aug 7, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Paper out June 29 2014

    by mrbutters334 Jul 29, 2014 11:04 AM
    mrbutters334 mrbutters334 Jul 30, 2014 11:33 AM Flag

    If you read my post more carefully instead of rushing to discredit me or anyone else who thinks this company can turn around. you would of seen that the article of June 29 2014 has to do with prostate cancer and is not the article you are stating in 2013 that deals with pancreatic cancer. Maybe you should get your facts straight. If Ms Ward Cleaver could find it I think you could too. If you can't just ask MS Ward Cleaver for her help.

  • Unlike a drug which works on some people and not on others AEZS-130 is a test. It either works or it don't. There is no in between. Since it is documented how well it works and it is oral instead of iv injected the chance of approval is high. Also another use can be for testing HGH human growth hormones in athletes.NFL,NBA, MLB, NCAA could be big customers besides all the other testing AEZS-130 can be used for. Since AEZS has the worldwide rights for this test the revenue could easily be in the 100 millions.

  • Reply to

    Paper out June 29 2014

    by mrbutters334 Jul 29, 2014 11:04 AM
    mrbutters334 mrbutters334 Jul 29, 2014 11:44 PM Flag

    Paper was published in June 2014, Dr Schally is a co-inventor, he also won the Noble prize for medicine in 1977. Who pays you to write all these novellas about AEZS? You never gave us a reason why you are so obsessed with AEZS being you stated before you own no stock. Maybe you should of been on GALT or TRGTs board to warn them about their stock or some of the other bios that tumbled lately and helped all those investors that lost money. .This is a $1.20 stock, no one in their right mind would write as much as you do unless you had allterior motives. Your the same as it ever was. Your are the endless talking head.

  • mrbutters334 by mrbutters334 Jul 29, 2014 11:04 AM Flag

    Very technical but very positive on aezs-108 in Academia edu.
    Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels
    by Ferenc Rick

  • Reply to

    AEZS is undervalued

    by mrbutters334 Jul 21, 2014 8:50 AM
    mrbutters334 mrbutters334 Jul 21, 2014 9:42 AM Flag

    Thanks entropy , my mistake, meant aezs-108 is the delivery system.

  • mrbutters334 by mrbutters334 Jul 21, 2014 8:50 AM Flag

    Some posters like dsco keep bringing up the past failures of AEZS. The main one a few years ago was perifosine. Remember AEZS licensed the drug to KERX and they ran the trial, it was not AEZS. With the FDA decision coming in Nov. and the phase 3 trial for AEZS-130 running at a good pace AEZS have should a lot more potential than what Wainright said because AEZS-130 could be used for other cancers since it is a delivery system. AEZS is like someone who was in a car accident. the prognosis's looks bleak but with rehab the patient improves. Same with AEZS ,it is making moves to be a viable company and the future looks promising. There have been many bio turnaround companies remember KERX was 20 cents once.

  • mrbutters334 by mrbutters334 Jul 11, 2014 12:40 PM Flag

    Stock Money Flow WSJ
    Money flow gives a snapshot of relative buying and selling pressure in a stock.
    A ratio above one suggests greater buying pressure, below one suggests greater selling.
    Uptick/Downtick Trade Ratio
    +2.00
    Net Money Flow+ $56,198

  • Reply to

    the science behind doxorubicin

    by nitabosco Jul 10, 2014 9:41 PM
    mrbutters334 mrbutters334 Jul 11, 2014 10:11 AM Flag

    The purpose of these new posters with spam is to bury posts like this.

  • Reply to

    the science behind aezs

    by nitabosco Jul 10, 2014 9:26 PM
    mrbutters334 mrbutters334 Jul 11, 2014 10:10 AM Flag

    Good Post.

  • mrbutters334 by mrbutters334 Jul 9, 2014 10:28 AM Flag

    still under heavy accumulation.
    Stock Money Flow WSJ
    Money flow gives a snapshot of relative buying and selling pressure in a stock.
    A ratio above one suggests greater buying pressure, below one suggests greater selling.
    Uptick/Downtick Trade Ratio
    + 1.31
    Net Money Flow +$2,285

  • mrbutters334 by mrbutters334 Jul 6, 2014 10:07 AM Flag

    Dsco now that the pps is going up your are posting in great lengths your negative remarks about AEZS more frequently. Teams use a full court press usually when they are behind and have to catch up when they are losing. As the price of AEZS goes up what you say has less meaning . You should be happy that the new investors are making some money on this stock since you state you have no investment in this stock.. But your not. I wonder why, but do appreciate you trying to save us from investing in this stock . Maybe one day you will tell us the real reason why your so interested in warning us not to invest in this stock since you don't have any skin in the game. Since you made your point here maybe you should find another stock where you can save the investors. The future looks bright for AEZS . No looking in the rear view mirror.

  • 1) It is a diagnostic test,so it either works or it don't.
    2) Got SPA from FDA.
    3) AEZS worked with FDA and the FDA will include the phase 3 trial that was started by Ardana whom AEZS bought the patent from and has the worldwide rights.
    . FDA required 100 subjects which AEZS followed their instructions.
    4) Trial results: A Phase 3 trial in AGHD has been completed. The parameters of the study were achieved as agreed to with the FDA under a Special Protocol Assessment (SPA). Importantly, the primary efficacy parameters showed that the study achieved both specificity and sensitivity at a level of 90% or greater. The use of MACRILENTM was shown to be safe and well tolerated overall throughout the completion of this trial.
    This will oral instead of intravenous this test will be preferred by almost 100% of the patients and doctors and with worldwide rights AEZS-130 will be a cash cow for AEZS. It is all about the future not the past.

  • mrbutters334 by mrbutters334 Jul 3, 2014 10:10 AM Flag

    Stock Money Flow WSJ

    About Money Flow
    Money flow gives a snapshot of relative buying and selling pressure in a stock.
    A ratio above one suggests greater buying pressure, below one suggests greater selling.
    Uptick/Downtick Trade Ratio
    + 3.02
    Net Money Flow +$195,394

  • mrbutters334 by mrbutters334 Jul 2, 2014 5:13 PM Flag

    All these idiots that come out of the woodwork. They were either short or looking for a lower price to buy in. . I hope bernjosii was short and loses all his money. He is a disgrace to himself. Just flag him and put him on ignore and report him.

  • mrbutters334 mrbutters334 Jul 2, 2014 10:29 AM Flag

    If you didn't mention that this basher added an extra i to your name I wouldn't have noticed it. He must be desperate and a real low life. Shame on him.

  • Reply to

    DCSOBASH - Noticably Absent

    by joligran Jul 2, 2014 10:08 AM
    mrbutters334 mrbutters334 Jul 2, 2014 10:16 AM Flag

    This bernstien keeps posting to hide the positive posts. Wouldn't be surprised if he was one of dcso cronies.

  • Reply to

    DCSOBASH - Noticably Absent

    by joligran Jul 2, 2014 10:08 AM
    mrbutters334 mrbutters334 Jul 2, 2014 10:13 AM Flag

    Dsco has no legs to stand on since he has been wrong lately with his predictions .
    AEZS under a dollar, r/s. crl, He will not admit that this company finally has potential and a company can turn around.

  • mrbutters334 by mrbutters334 Jul 2, 2014 9:45 AM Flag

    Last few weeks heavy accumulation.

  • mrbutters334 mrbutters334 Jul 2, 2014 8:45 AM Flag

    Great article. Just shows that if AEZS-108 is successful in Endometrial cancer it will work with other cancers as well. Like I said before since this is an open label trial with many people involved. Something very positive had to be leaked out since first dosing was a year ago... Good chance for major partnership Such a bargain at these prices..

  • mrbutters334 by mrbutters334 Jul 1, 2014 8:19 AM Flag

    The phase 3 trial for aezs-108 began last July. it is an open label trial meaning all patients get the drug. With hundreds of patients and thousands of families and administraters seeing the progress of the drug maybe some are seeing that it is working. Since aezs-108 is a delivery system and can work with many cancers if it works then the stock will see huge gains. Also with aezs-130 filed with the FDA and and answer on Nov.6 this is a bonus. Stock is way undervalued.

AEZS
1.14-0.04(-3.39%)Aug 1 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Icahn Enterprises, L.P.
NasdaqGSFri, Aug 1, 2014 3:59 PM EDT
Marriott International, Inc.
NasdaqGSFri, Aug 1, 2014 4:00 PM EDT